(Q53027947)

10 May 2018

review article

1 reference

title

Manufacturing DTaP-based combination vaccines: industrial challenges around essential public health tools. (English)

1 reference

10 May 2018

author name string

Emmanuel Vidor

series ordinal

1

1 reference

10 May 2018

Benoit Soubeyrand

series ordinal

2

1 reference

10 May 2018

publication date

27 June 2016

1 reference

10 May 2018

Expert Review of Vaccines

published in

1 reference

10 May 2018

volume

15

1 reference

10 May 2018

issue

12

1 reference

10 May 2018

page(s)

1575-1582

1 reference

10 May 2018

Combined and simultaneously administered vaccines. A brief history.

cites work

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

New combination vaccines: integration into pediatric practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

New acellular pertussis-containing paediatric combined vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Pediatric combination vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Health economic research on vaccinations and immunisation practices--an introductory primer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Hexavalent vaccines for immunization in paediatric age

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody level

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Manufacturing of biodrugs: need for harmonization in regulatory standards

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Reaching international GMP standards for vaccine production: challenges for developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Vaccine industry perspective of current issues of good manufacturing practices regarding product inspections and stability testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Manufacturing issues with combining different antigens: a regulatory perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Manufacturing issues related to combining different antigens: an industry perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Defining and characterizing drug/compound function

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

State-of-the-art in downstream processing of monoclonal antibodies: process trends in design and validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Vaccine adjuvant formulations: a pharmaceutical perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Aluminium compounds for use in vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Detoxification of endotoxin by aluminum hydroxide adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Influence of elemental impurities in aluminum hydroxide adjuvant on the stability of inactivated Japanese Encephalitis vaccine, IXIARO®.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Study of the chemical stability of the capsular polysaccharide produced by Haemophilus influenzae type b.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Relationship of immunogenicity to protective potency in acellular pertussis vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Quality-control issues and approaches in vaccine development

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Defining long-term drivers of pertussis resurgence, and optimal vaccine control strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

Can quality solve the equation? {Downarrow} pricing + {uparrow} health authority expectations + {uparrow} supply chain complexity + {uparrow} counterfeiting = quality drugs to patients + an engaged workforce.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F14760584.2016.1205492

10.1080/14760584.2016.1205492

21 January 2018

Identifiers

DOI

1 reference

10 May 2018

release_bqumupgtunhvvmgf3m73telduu

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bqumupgtunhvvmgf3m73telduu

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

10 May 2018